Company Focus
Teva Pharmaceutical Industries
Latest Teva Pharmaceutical Industries News
Generics
Israel’s Teva Pharmaceutical Industries today reported results for the quarter ended March 31, 2025. 7 May 2025
Related News
Insights
Company Spotlight
Compugen is a genomics-based drug and diagnostic discovery company.
Latest News & Features of interest to Teva Pharmaceutical Industries
Biotechnology
UK-based Kaerus Bioscience, a biopharma created by European investment firm Medicxi for the development of therapeutics for rare genetic syndromes of neurodevelopment, has announced that its lead candidate KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the US Food and Drugs Administration (FDA). 14 May 2025
Pharmaceutical
New York-based Axsome Therapeutics, a biopharma focused on central nervous system (CNS) disorders, has entered into a $570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and Blackstone Credit and Insurance. 14 May 2025
Pharmaceutical
Danish CNS specialist Lundbeck today released first-quarter 2025 financials, along with a raised guidance for the full year, sending its shares up more than 9% to 28.80 kroner. 14 May 2025
Biotechnology
Belgian biotech Galapagos is pausing its high-profile plan to break into two separate businesses, just five months after unveiling the ambitious strategy. The company also confirmed a sudden change in leadership, with Henry Gosebruch stepping in as chief executive effective immediately. 14 May 2025
Biotechnology
Belgian clinical-stage biotech iTeos Therapeutics saw its shar leap18.6% to $8.20 today, despite posting disappointing results for a leading program and decision to discontinue GALAXIES Lung-201, the Phase II platform study sponsored by iTeos’ development partner GSK assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer (NSCLC). 13 May 2025
Biotechnology
Privately-held Remedy Plan Therapeutics, a US pharma company developing novel, hyperbolic NAMPT inhibitors, has raised more than $18 million in an oversubscribed insider financing round. 13 May 2025
Pharmaceutical
German life sciences company Bayer presented its first-quarter financial results and latest guidance for 2025 on Tuesday. 13 May 2025
Pharmaceutical
Hungary’s largest drugmaker Gedeon Richter has announced its financial results for the first quarter of 2025, sending its shares up 2.2% to 26.46 euros. 13 May 2025
Biotechnology
Swiss pharma giant Roche, the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, today announced statistically-significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. 13 May 2025
Pharmaceutical
Chinese biotech Minghui Pharmaceutical has sold certain rights to its experimental cancer drug MHB088C to Qilu Pharmaceutical in a licensing deal worth up to $177 million. 12 May 2025
Latest In Brief for Teva Pharmaceutical Industries
Biotechnology
The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan concentrate for solution for infusion 100mg for an additional indication, according to a Healthcare Radius report. 12 May 2025
Latest Relevant Ones To Watch News
Belgian biotech Galapagos is pausing its high-profile plan to break into two separate businesses, just five months after unveiling the ambitious strategy. The company also confirmed a sudden change in leadership, with Henry Gosebruch stepping in as chief executive effective immediately. 14 May 2025
28 April 2025
28 April 2025
17 April 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze